menu
    • menu
    [{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Human Interferon Alfa","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Kexing Biopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Biopharm \/ Not Applicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"GB08","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Kexing Biopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kexing Biopharm \/ Not Applicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Human Interferon Alfa","moa":"IFNAR-1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kexing Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kexing Biopharm \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Kexing Biopharm

    Menu

    Kexing Biopharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kexing Biopharm

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Kexing Biopharm

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kexing Biopharm Obtained IND Approval for its Self-developed GB05 from U.S. FDA

                            Details : GB05 (human interferon alpha-1b) is an inhalation solution, which is being evaluated for the treatment of respiratory syncytial virus infections in children..

                            Product Name : GB05

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 14, 2025

                            Lead Product(s) : Human Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kexing Biopharm

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Kexing Biopharm

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval

                            Details : Apexelsin (albumin bound-paclitaxel) a microtubule inhibitor indicated for metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer & metastatic pancreatic adenocarcinoma.

                            Product Name : Apexelsin

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            July 31, 2024

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kexing Biopharm

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Kexing Biopharm

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GB08

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kexing Gets Approval for Trial of Long-Acting Growth Hormone Drug

                            Details : GB08 is a long-acting growth hormone in the form of an Fc-fusion protein, which is being evaluated for the treatment of patients with pediatric growth hormone deficiency syndrome.

                            Product Name : GB08

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 30, 2024

                            Lead Product(s) : GB08

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kexing Biopharm

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            Kexing Biopharm

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kexing Biopharm Enrolls Subjects In Phase III Trial For Inhaled Aerosol Drug In Children

                            Details : The company has developed GB05 (human interferon alpha-1b) inhalation solution, which is being evaluated for the treatment of respiratory syncytial virus infections in children under 2 years of age.

                            Product Name : GB05

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 09, 2024

                            Lead Product(s) : Human Interferon Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth